Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine

A Brisuda, J Hacek, M Cechova, P Skapa, M Babjuk

. 2019 ; 30 (5) : 510-518.

Jazyk angličtina Země Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20018127

Grantová podpora
NV15-33266A MZ0 CEP - Centrální evidence projektů

OBJECTIVE: Immunocytochemistry has attained a marginal role in urology so far. Combining the morphological and immunophenotypical changes of the urothelial cells retrieved from urine is a logical approach. The study aimed to analyse the diagnostic potential of immunocytological staining in the detection of high-grade and low-grade urothelial carcinoma. METHODS: Freshly voided urine was collected from 152 consecutive individuals, cytology classes were determined and cell blocks produced. A total of 77 patients were diagnosed with urothelial carcinoma and 75 patients had various benign urological conditions. Immunocytochemistry was performed using four antibodies: p53, MCM2, MCM5 and Ki-67. A diagnostic power to detect low grade and high-grade urothelial carcinoma was analysed for each antibody and their combinations with cytology. RESULTS: There were no significant differences between patients with low-grade tumours and control group. Antibodies p53 and Ki-67 slightly improved the sensitivity of urinary cytology while maintaining its specificity. The best negative predictive value was demonstrated in combinations of cytology and MCM5 (88.9%) and cytology, p53 and MCM5 (90.6%). In the diagnosis of high-grade tumours, all antibodies apart from MCM2 yielded better sensitivity and specificity than cytology alone (receiver operating characteristic curves: p53 = 0.853, MCM5 = 0.931, and Ki-67 = 0.895). Combined with cytology, the sensitivities went even higher for the cost of lower specificity. The best diagnostic performance was observed in the combination of MCM5 and Ki-67 (sensitivity = 96.2%; specificity = 80%). CONCLUSIONS: Immunocytochemistry with p53, MCM5 and Ki-67 antibodies can improve the diagnostic power of urinary cytology in the detection and follow-up of urinary bladder urothelial carcinoma. Copyright © 2019 John Wiley & Sons Ltd.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20018127
003      
CZ-PrNML
005      
20201119084904.0
007      
ta
008      
201112s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/cyt.12698 $2 doi
035    __
$a (PubMed)30943322
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Brisuda, Antonín, $d 1980- $7 xx0208968 $u Department of Urology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine / $c A Brisuda, J Hacek, M Cechova, P Skapa, M Babjuk
520    9_
$a OBJECTIVE: Immunocytochemistry has attained a marginal role in urology so far. Combining the morphological and immunophenotypical changes of the urothelial cells retrieved from urine is a logical approach. The study aimed to analyse the diagnostic potential of immunocytological staining in the detection of high-grade and low-grade urothelial carcinoma. METHODS: Freshly voided urine was collected from 152 consecutive individuals, cytology classes were determined and cell blocks produced. A total of 77 patients were diagnosed with urothelial carcinoma and 75 patients had various benign urological conditions. Immunocytochemistry was performed using four antibodies: p53, MCM2, MCM5 and Ki-67. A diagnostic power to detect low grade and high-grade urothelial carcinoma was analysed for each antibody and their combinations with cytology. RESULTS: There were no significant differences between patients with low-grade tumours and control group. Antibodies p53 and Ki-67 slightly improved the sensitivity of urinary cytology while maintaining its specificity. The best negative predictive value was demonstrated in combinations of cytology and MCM5 (88.9%) and cytology, p53 and MCM5 (90.6%). In the diagnosis of high-grade tumours, all antibodies apart from MCM2 yielded better sensitivity and specificity than cytology alone (receiver operating characteristic curves: p53 = 0.853, MCM5 = 0.931, and Ki-67 = 0.895). Combined with cytology, the sensitivities went even higher for the cost of lower specificity. The best diagnostic performance was observed in the combination of MCM5 and Ki-67 (sensitivity = 96.2%; specificity = 80%). CONCLUSIONS: Immunocytochemistry with p53, MCM5 and Ki-67 antibodies can improve the diagnostic power of urinary cytology in the detection and follow-up of urinary bladder urothelial carcinoma.<ovid:br/><ovid:br/> Copyright &#xa9; 2019 John Wiley & Sons Ltd.
650    02
$a senioři $7 D000368
650    12
$a protilátky nádorové $x imunologie $7 D000912
650    02
$a nádorové biomarkery $x metabolismus $7 D014408
650    12
$a proteiny buněčného cyklu $x imunologie $7 D018797
650    12
$a cytodiagnostika $7 D003581
650    02
$a ženské pohlaví $7 D005260
650    02
$a lidé $7 D006801
650    02
$a imunohistochemie $7 D007150
650    12
$a antigen Ki-67 $x imunologie $7 D019394
650    02
$a mužské pohlaví $7 D008297
650    12
$a MCM komplex, komponenta 2 $x imunologie $7 D064111
650    02
$a stupeň nádoru $7 D060787
650    02
$a ROC křivka $7 D012372
650    02
$a senzitivita a specificita $7 D012680
650    12
$a nádorový supresorový protein p53 $x imunologie $7 D016159
650    12
$a nádory močového měchýře $x diagnóza $x patologie $7 D001749
650    12
$a moč $x cytologie $7 D014556
700    1_
$a Háček, Jaromír $7 xx0236643 $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Fontana, Marcela $7 pna20241220860 $u Department of Urology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Škapa, Petr $7 xx0105776 $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Babjuk, Marko, $d 1961- $7 jn20020716353 $u Department of Urology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$t Cytopathology $g Roč. 30, č. 5 (2019), s. 510-518 $p Cytopathology $x 0956-5507 $w MED00009532
773    0_
$p Cytopathology $g 30(5):510-518, 2019 09
910    __
$a ABA008 $y p $z 0
990    __
$a 20201112210332 $b ABA008
991    __
$a 20201119084901 $b ABA008
999    __
$a ok $b bmc $g 1582057 $s 1108324
BAS    __
$a 3
BMC    __
$a 2019 $b 30 $c 5 $d 510-518 $x MED00009532 $i 0956-5507 $m Cytopathology
GRA    __
$a NV15-33266A $p MZ0
LZP    __
$a 2020-lp

Najít záznam

Citační ukazatele

Možnosti archivace